NASDAQ:KPRX Kiora Pharmaceuticals Q3 2026 Earnings Results & Report $1.28 -0.05 (-3.38%) As of 12:41 PM Eastern This is a fair market value price provided by Massive. Learn more. Kiora Pharmaceuticals beat analyst earnings expectations in its Q3 2026 results, released November 12, 2026. The company reported EPS of -$0.28 versus the -$0.38 consensus estimate, while revenue was $1 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 12, 2026TimeBefore Market OpensConference Call7:00 AM ET Kiora Pharmaceuticals EPS ResultsActual EPS-$0.28Consensus EPS -$0.38Beat/MissBeat by +$0.10One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersKiora Pharmaceuticals Revenue ResultsActual Revenue$1 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Kiora Pharmaceuticals Q3 2026 Earnings FAQ Did Kiora Pharmaceuticals beat earnings estimates for Q3 2026? Kiora Pharmaceuticals (NASDAQ:KPRX) reported earnings of -$0.28 per share for Q3 2026, beating the consensus estimate of -$0.38. The report was announced on Thursday, November 12, 2026. What was Kiora Pharmaceuticals' revenue for Q3 2026? Kiora Pharmaceuticals reported revenue of $1 million for Q3 2026. Kiora Pharmaceuticals Earnings HeadlinesKiora Pharmaceuticals Faces High-Stakes Risk in KIO-401 Deal with Senju as 2040 Regulatory Deadline LoomsNovember 13 at 1:10 AM | tipranks.comKiora Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateNovember 12 at 8:07 AM | finance.yahoo.comI'm handing you this stock todayElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.November 13 at 1:00 AM | Behind the Markets (Ad)Analysts Are Bullish on Top Healthcare Stocks: PTC Therapeutics (PTCT), Stryker (SYK)November 1, 2026 | theglobeandmail.comKiora Pharmaceuticals In-Licenses Late-Stage, Oral Neuroprotective Calpain Inhibitor for Central Retinal Artery Occlusion (CRAO) with Planned Expansion into NAION; Asset ...October 29, 2026 | finance.yahoo.comKiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory AffairsSeptember 8, 2026 | finance.yahoo.comSee More Kiora Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Kiora Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kiora Pharmaceuticals and other key companies, straight to your email. Email Address About Kiora PharmaceuticalsKiora Pharmaceuticals (NASDAQ:KPRX) is a clinical-stage biotechnology company focused on developing therapies for diseases of the eye. The company’s research programs are aimed at addressing conditions with limited treatment options, including inherited retinal diseases and inflammatory eye disorders. Kiora’s lead program, KIO-301, is an investigational small-molecule therapy designed to function as a molecular photoswitch. The company is studying its potential to restore light perception in patients with vision loss caused by retinal degeneration, including retinitis pigmentosa. Kiora has also been developing KIO-104, an investigational therapy intended to treat non-infectious uveitis and other ocular inflammatory conditions. The company’s programs have been evaluated through clinical development activities in the United States and other countries, including Australia. Kiora Pharmaceuticals is headquartered in the United States and trades on the Nasdaq Capital Market under the symbol KPRX.View Kiora Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Costco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsThese 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went ShoppingGolden Dome’s $185 Billion Question: Who Actually Gets Paid?3 Pharmaceutical Stocks That Offer Safety and GrowthFirefly Aerospace Lights Up a High-Risk Space Opportunity Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
